Clough Capital Partners L P Biomarin Pharmaceutical Inc Transaction History

Clough Capital Partners L P

$924 Million
Q3 2024

A detailed history of Clough Capital Partners L P transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Clough Capital Partners L P holds 3,580 shares of BMRN stock, worth $241,220. This represents 0.03% of its overall portfolio holdings.

Number of Shares

3,580

Previous 3,580 -0.0%

Holding current value

$241,220

Previous $294,000 14.63%

% of portfolio

0.03%

Previous 0.03%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $3.78 Million - $4.19 Million	-44,390 Reduced 92.54%	3,580 $316,000
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $4.16 Million - $4.81 Million	47,970 New	47,970 $4.16 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $4.76 Million - $6.02 Million	-70,689 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $56,244 - $65,730	-700 Reduced 0.98%	70,689 $6.06 Million
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $842,000 - $986,200	10,000 Added 16.29%	71,389 $6.34 Million
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $2.04 Million - $2.7 Million	25,444 Added 70.79%	61,389 $5.23 Million
Q3 2018 Nov 14, 2018	SELL	$93.92 - $105.72 $422,640 - $475,740	-4,500 Reduced 11.13%	35,945 $3.49 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $311,641 - $406,023	4,100 Added 11.28%	40,445 $3.81 Million
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $240,777 - $287,153	-3,100 Reduced 7.86%	36,345 $2.95 Million
Q4 2017 Feb 14, 2018	SELL	$80.76 - $95.13 $742,992 - $875,196	-9,200 Reduced 18.91%	39,445 $3.52 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $3.92 Million - $4.62 Million	48,645	48,645 $4.53 Million

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.5B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Clough Capital Partners L P, based on Form 13F filings with the SEC.

News

Stay updated on Clough Capital Partners L P with notifications on news.

Account

Clough Capital Partners L P Biomarin Pharmaceutical Inc Transaction History